Last updated on March 2020

Study of Oral SKI-O-703 SYK Inhibitor in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)


Brief description of study

Study in patients with persistent and chronic Immune Thrombocytopenia (ITP), who have failed to respond or relapsed after prior therapy, with a platelet count <30,000/L. Patient will be randomly assigned in 2 groups with two dose levels of SKI-O-703 200mg BID, 400 mg BID, and placebo; administered orally twice a day.

Detailed Study Description

This study will evaluate the efficacy, safety, tolerability,pharmacokinetics (PK), and pharmacodynamics (PD) of select (200 mg BID and 400 mg BID) doses of SKI-O-703 in persistent and chronic ITP patients who have failed to respond or relapsed after prior therapy, with a platelet count <30,000/L. on 2 occasions at least 7 days apart with the confirmatory count on the first day of treatment.

subjects will participate in 3 treatment groups (24 subjects in each of the active treatment groups and 12 subjects in the placebo group). The total study duration will be 20 weeks per subject, which consists of up to 4 weeks of screening period, 12 weeks of treatment period, and 4 weeks of follow-up period.

Clinical Study Identifier: NCT04056195

Find a site near you

Start Over

Hospital Universitario Quironsalud Madrid

Pozuelo De Alarcón, Spain
3.73miles
  Connect »

Hospital Universitario Quironsalud Madrid

Pozuelo De Alarcón, Spain
3.73miles
  Connect »